XNCR Xencor Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XNCR

Price (delayed)

$27.25

Market cap

$1.65B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.35

Enterprise value

$1.63B

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights
XNCR's quick ratio is up by 19% year-on-year but it is down by 9% since the previous quarter
The EPS has shrunk by 153% QoQ
The company's net income has shrunk by 153% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xencor.com
Peers: SGEN MGNX AMGN JNJ

Key stats

What are the main financial stats of XNCR
Market
Shares outstanding
60.39M
Market cap
$1.65B
Enterprise value
$1.63B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.39
Price to sales (P/S)
16.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.65
Earnings
Revenue
$98.05M
EBIT
-$138.87M
EBITDA
-$130M
Free cash flow
-$59.13M
Per share
EPS
-$2.35
Free cash flow per share
-$0.99
Book value per share
$11.39
Revenue per share
$1.64
TBVPS
$13.14
Balance sheet
Total assets
$803.41M
Total liabilities
$119.83M
Debt
$59.24M
Equity
$683.58M
Working capital
$564.92M
Liquidity
Debt to equity
0.09
Current ratio
9.68
Quick ratio
9.34
Net debt/EBITDA
0.1
Margins
EBITDA margin
-132.6%
Gross margin
100%
Net margin
-142.3%
Operating margin
-171.7%
Efficiency
Return on assets
-16.7%
Return on equity
-19.4%
Return on invested capital
-18.9%
Return on capital employed
-18.8%
Return on sales
-141.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XNCR stock price

How has the Xencor stock price performed over time
Intraday
0.29%
1 week
-0.73%
1 month
1.3%
1 year
21.87%
YTD
4.65%
QTD
-2.29%

Financial performance

How have Xencor's revenue and profit performed over time
Revenue
$98.05M
Gross profit
$98.05M
Operating income
-$168.31M
Net income
-$139.54M
Gross margin
100%
Net margin
-142.3%
The company's net income has shrunk by 153% QoQ
Xencor's operating income has plunged by 104% from the previous quarter
XNCR's revenue has dropped by 70% year-on-year and by 40% since the previous quarter
The gross profit has plunged by 70% YoY and by 40% from the previous quarter

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation
P/E
N/A
P/B
2.39
P/S
16.61
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.65
The EPS has shrunk by 153% QoQ
XNCR's P/B is 25% below its 5-year quarterly average of 3.2 but 9% above its last 4 quarters average of 2.2
XNCR's equity is down by 10% year-on-year and by 6% since the previous quarter
XNCR's P/S is 79% above its last 4 quarters average of 9.3 but 15% below its 5-year quarterly average of 19.5
XNCR's revenue has dropped by 70% year-on-year and by 40% since the previous quarter

Efficiency

How efficient is Xencor business performance
XNCR's ROE has plunged by 159% from the previous quarter
The ROIC has plunged by 159% from the previous quarter
The ROA has plunged by 157% from the previous quarter

Dividends

What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time
XNCR's total liabilities is up by 26% year-on-year
XNCR's quick ratio is up by 19% year-on-year but it is down by 9% since the previous quarter
Xencor's debt is 91% lower than its equity
The debt to equity has soared by 80% YoY and by 13% from the previous quarter
Xencor's debt has surged by 70% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.